Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00447356
Status:
WITHDRAWN
Last Update Posted:
2013-05-13
First Post:
2007-03-12
Brief Title:
High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma
Sponsor:
Hackensack Meridian Health
Organization:
Hackensack Meridian Health
Study Overview
Official Title:
Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 Microscopic Melanoma
Status:
WITHDRAWN
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
There were no patient enrolled in this study at this site
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery
Detailed Description:
Interferon alfa may interfere with growth of cancer cells It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None